To Get Full Access :

Letybo

Letybo is an injectable neurotoxin used to soften frown lines between the eyebrows by temporarily relaxing the muscles responsible. It works by blocking acetylcholine release at the neuromuscular junction, reducing muscle contractions and smoothing wrinkles.

The information outlined in the molecule details section below would help you plan aBLA development early to enable a streamlined and competitive biosimilar strategy.

Molecule Details :

  • Molecule Name :

    Letibotulinumtoxina-Wlbg
  • Innovator :

    HUGEL, INC.
  • Approval Date :

    29-Feb-24
  • Data Exclusivity Expiry :

    29-Feb-28
  • Market Exclusivity Expiry :

    29-Feb-36
  • Dosage Form :

    IM Injection
  • Strength :

    50 units per vial and 100 units per vial
  • Therapeutic Category :

    Dermatologic
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    NA
  • 2026 :

    NA
  • 2027 :

    NA
  • 2028 :

    NA
  • 2029 :

    NA
  • 2030 :

    NA
  • 2031 :

    NA
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?